摘要
目的:研究射贝止咳液对小儿咳嗽变异性哮喘中IFN-γ、IL-4表达的影响。方法:将95例咳嗽变异性哮喘(CVA)患儿随机分为2组,治疗组50例,口服射贝止咳液;对照组45例,口服酮替芬。2组均在用药前后分别记录患儿症状、体征及检测干扰素-γ(IFN-γ)、白介素-4(IL-4)的表达水平,并进行比较。结果:治疗组50例中显效39例,有效10例,无效1例,总有效率98%;对照组45例中,显效25例,有效14例,无效6例,总有效率86.67%。治疗组临床疗效明显优于对照组(P<0.05)。治疗组和对照组在治疗前IFN-γ、IL-4均无显著性意义(P>0.05),治疗后以上指标组内相比差异显著(P<0.01),且治疗组中IFN-γ、IL-4表达更加明显(P<0.05)。结论:射贝止咳液治疗小儿CVA疗效明显优于酮替芬,主要通过抑制IL-4水平及提高IFN-γ水平,使Th1/Th2失衡得到一定程度的纠正,减少病理活性产物的释放,从而控制气道炎症,减缓哮喘发作。
Objective： To study the effects of SheBei ZhiKe oral liquid on the expressions of interferon-y （IFN-y） and interleukin-4（IL-4） of children with cough variant asthma （CVA）. Method： All 95 patients were randomized into 50 cases in the treatment group and 45 cases in the control group, the treatment group took SheBei ZhiKe oral liquid and the control group ketotifen. The symptoms and body signs were recorded before and after administration, the levels of IFN-y and IL-4 expressions were tested and compared between both groups. Result： All 39 cases were improved greatly, ten cases effective, one case ineffective among 50 cases of the treatment group, total effective rate was 98%; 25 cases were markedly effective, 14 cases effective and six cases ineffective, total effective rate was 86.67% among 45 cases of the control group, clinical effects of the treatment group were superior to the control group remarkably （P〈0.05）. Comparisons between both group showed no significant meaning in IFN-y and IL-4 be- fore treating （P〉 0.05）, the comparisons after treating had notable difference （P〈0.01）, IFN-T and IL-4 expressed more significant in the treatment group（P〈0.05）. Conclusion： Clinical effects of SheBei ZhiKe oral liquid in treating children with CVA are superior to ketotifen, which could correct the imbalance of Th1/Th2, reduce the release of pathological activated products through inhibiting the level of IL-4 and raise the level of IFN-y, therefore to control the airway inflammation and alleviate the attack of asthma.
出处
《西部中医药》
2013年第7期14-16,共3页
Western Journal of Traditional Chinese Medicine
基金
甘肃省中医药科研项目(编号GZK-2008-18)
